Matthew Henn | SVP, Head of Drug Discovery & Bioinformatics
Seres Therapeutics

Matthew Henn, SVP, Head of Drug Discovery & Bioinformatics, Seres Therapeutics

Matthew Henn

Senior VP, Head of Drug Discovery and Bioinformatics, Seres Therapeutics

Matthew Henn is the Senior Vice President and Head of Drug Discovery & Bioinformatics of Seres. He has more than 16 years of combined research experience in microbial ecology, genomics, and bioinformatics that spans both environmental and infectious disease applications. Dr. Henn's research has focused on the development, implementation, and application of genomic technologies in the area of microbial populations and their metabolic functions. Prior to joining Seres, he was the Director of Viral Genomics and Assistant Director of the Genome Sequencing Center for Infectious Diseases at the Broad Institute of MIT and Harvard.

He has authored over 60 peer-reviewed publications in microbiology and bioinformatics, and has led multiple large-scale international genomic projects. He has served as a consultant for the WHO’s Grand Challenges in Genomics for Public Health in Developing Countries, as a scientific advisor for the National Institutes of Health’s Viral Pathogen Bioinformatics Resource Center, and as an ad-hoc reviewer and editor of many peer-reviewed journals. Dr. Henn earned his Ph.D. in ecosystem sciences from the University of California at Berkeley, where he was a NASA Earth Systems Sciences Fellow, and trained as a NSF Postdoctoral Fellow in microbiology at Duke University.

Appearances:



Microbiome World Congress USA Day 2 2017 @ 09:20

Plenary Panel: Regulations in response to the Microbiome

Plenary
  • How do you work with regulators in development of Microbiome treatments?
  • How do you prevent Wild West scenarios where many companies are promoting their product and operating without oversight?
  • From FMT, Prebiotics to Probiotics, from food supplements to traditional treatments- what protocols must be established for such a wide variety of products?
  • What standards are necessary and what does solid translational evidence look like in judging the efficacy of microbial treatments?

back to speakers